NO326601B1 - Fibrin-tetningsmidler eller -ad-hesiver inneholdende et hyaluronsyrederivat-materiale - Google Patents

Fibrin-tetningsmidler eller -ad-hesiver inneholdende et hyaluronsyrederivat-materiale Download PDF

Info

Publication number: NO326601B1
Authority: NO; Norway
Prior art keywords: fibrin; hyaluronic acid; accordance; preparation; fibrinogen
Prior art date: 1997-11-17

Application number

NO20002357A

Other languages

English (en)

Norwegian (no)

Other versions

NO20002357L (no

NO20002357D0 (no

Inventor

Ira Weisberg

Elaine Whitmore

Marc R Paquin

Original Assignee

Haemacure Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-17

Filing date

2000-05-05

Publication date

2009-01-19

2000-05-05 Application filed by Haemacure Corp filed Critical Haemacure Corp

2000-05-05 Publication of NO20002357D0 publication Critical patent/NO20002357D0/no

2000-06-14 Publication of NO20002357L publication Critical patent/NO20002357L/no

2009-01-19 Publication of NO326601B1 publication Critical patent/NO326601B1/no

Links

239000000463 material Substances 0.000 title claims abstract description 32
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 31
108010073385 Fibrin Proteins 0.000 title claims description 29
102000009123 Fibrin Human genes 0.000 title claims description 29
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims description 29
229950003499 fibrin Drugs 0.000 title claims description 29
239000000565 sealant Substances 0.000 title description 4
239000002671 adjuvant Substances 0.000 title 1
238000002360 preparation method Methods 0.000 claims abstract description 54
108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims abstract description 34
108010049003 Fibrinogen Proteins 0.000 claims abstract description 22
102000008946 Fibrinogen Human genes 0.000 claims abstract description 22
229940012952 fibrinogen Drugs 0.000 claims abstract description 22
229960004072 thrombin Drugs 0.000 claims abstract description 22
108090000190 Thrombin Proteins 0.000 claims abstract description 21
102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 14
108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 14
239000003114 blood coagulation factor Substances 0.000 claims abstract description 14
239000013543 active substance Substances 0.000 claims abstract description 9
230000001567 anti-fibrinolytic effect Effects 0.000 claims abstract description 5
239000000504 antifibrinolytic agent Substances 0.000 claims abstract description 5
229940082620 antifibrinolytics Drugs 0.000 claims abstract description 5
239000003381 stabilizer Substances 0.000 claims abstract description 4
229920002674 hyaluronan Polymers 0.000 claims description 28
229960003160 hyaluronic acid Drugs 0.000 claims description 25
239000012620 biological material Substances 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 10
-1 hyaluronic acid ester Chemical class 0.000 claims description 8
238000001356 surgical procedure Methods 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
239000003102 growth factor Substances 0.000 claims description 7
108090000790 Enzymes Proteins 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
229940088598 enzyme Drugs 0.000 claims description 5
239000012528 membrane Substances 0.000 claims description 5
238000007789 sealing Methods 0.000 claims description 4
239000004753 textile Substances 0.000 claims description 4
210000000115 thoracic cavity Anatomy 0.000 claims description 4
239000002435 venom Substances 0.000 claims description 4
210000001048 venom Anatomy 0.000 claims description 4
231100000611 venom Toxicity 0.000 claims description 4
241000271513 Bothrops jararacussu Species 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
239000003242 anti bacterial agent Substances 0.000 claims description 3
229940088710 antibiotic agent Drugs 0.000 claims description 3
229940019700 blood coagulation factors Drugs 0.000 claims description 3
238000013130 cardiovascular surgery Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 2
108010039627 Aprotinin Proteins 0.000 claims description 2
108010071289 Factor XIII Proteins 0.000 claims description 2
108010094028 Prothrombin Proteins 0.000 claims description 2
230000002491 angiogenic effect Effects 0.000 claims description 2
230000001772 anti-angiogenic effect Effects 0.000 claims description 2
229940034982 antineoplastic agent Drugs 0.000 claims description 2
239000002246 antineoplastic agent Substances 0.000 claims description 2
229960004405 aprotinin Drugs 0.000 claims description 2
230000010261 cell growth Effects 0.000 claims description 2
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
229940012444 factor xiii Drugs 0.000 claims description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 2
230000007170 pathology Effects 0.000 claims description 2
239000003998 snake venom Substances 0.000 claims description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
230000004069 differentiation Effects 0.000 claims 1
238000005507 spraying Methods 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 7
239000000470 constituent Substances 0.000 abstract 1
238000000034 method Methods 0.000 description 15
206010052428 Wound Diseases 0.000 description 8
208000027418 Wounds and injury Diseases 0.000 description 8
239000000853 adhesive Substances 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000003292 glue Substances 0.000 description 6
238000012552 review Methods 0.000 description 6
230000001070 adhesive effect Effects 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
208000032843 Hemorrhage Diseases 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000000694 effects Effects 0.000 description 3
229940099552 hyaluronan Drugs 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000008439 repair process Effects 0.000 description 3
238000002271 resection Methods 0.000 description 3
108010027612 Batroxobin Proteins 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
208000031737 Tissue Adhesions Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000013466 adhesive and sealant Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
239000001166 ammonium sulphate Substances 0.000 description 2
229940030225 antihemorrhagics Drugs 0.000 description 2
229960002210 batroxobin Drugs 0.000 description 2
108010038522 calobin Proteins 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
239000002874 hemostatic agent Substances 0.000 description 2
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229940068942 topical hemo-stat Drugs 0.000 description 2
241000271045 Agkistrodon contortrix contortrix Species 0.000 description 1
101000772006 Bombus ignitus Venom serine protease Bi-VSP Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
208000002251 Dissecting Aneurysm Diseases 0.000 description 1
241001269524 Dura Species 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
241001494884 Gloydius ussuriensis Species 0.000 description 1
206010018852 Haematoma Diseases 0.000 description 1
208000034693 Laceration Diseases 0.000 description 1
102100037611 Lysophospholipase Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
241000404883 Pisa Species 0.000 description 1
101710111620 Protein C activator Proteins 0.000 description 1
206010040102 Seroma Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000271897 Viperidae Species 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000008512 biological response Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011982 device technology Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
239000012374 esterification agent Substances 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
210000000256 facial nerve Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000003328 fibroblastic effect Effects 0.000 description 1
230000003890 fistula Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
230000000025 haemostatic effect Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000012317 liver biopsy Methods 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
201000003144 pneumothorax Diseases 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000007483 tonsillectomy Methods 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000002759 woven fabric Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials

Landscapes

Health & Medical Sciences (AREA)
Surgery (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Materials For Medical Uses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

NO20002357A 1997-11-17 2000-05-05 Fibrin-tetningsmidler eller -ad-hesiver inneholdende et hyaluronsyrederivat-materiale NO326601B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6588497P	1997-11-17	1997-11-17
PCT/US1998/024605 WO1999025782A2 (fr)	1997-11-17	1998-11-17	Agents de scellement ou adhesifs comprenant un materiau derive d'acide hyaluronique

Publications (3)

Publication Number	Publication Date
NO20002357D0 NO20002357D0 (no)	2000-05-05
NO20002357L NO20002357L (no)	2000-06-14
NO326601B1 true NO326601B1 (no)	2009-01-19

Family

ID=22065793

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20002357A NO326601B1 (no)	1997-11-17	2000-05-05	Fibrin-tetningsmidler eller -ad-hesiver inneholdende et hyaluronsyrederivat-materiale

Country Status (6)

Country	Link
US (2)	US6503527B1 (fr)
EP (1)	EP1032367B1 (fr)
AT (1)	ATE439150T1 (fr)
CA (1)	CA2308462C (fr)
NO (1)	NO326601B1 (fr)
WO (1)	WO1999025782A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6440427B1 (en) *	1991-06-17	2002-08-27	Biovitrum Ab	Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
ATE439150T1 (de) *	1997-11-17	2009-08-15	Haemacure Corp	Ein hyaluronsäurederivat enthaltende fibrinsiegel-oder fibrinklebmasse
US6610043B1 (en) *	1999-08-23	2003-08-26	Bistech, Inc.	Tissue volume reduction
US7654998B1 (en)	1999-08-23	2010-02-02	Aeris Therapeutics, Inc.	Tissue volume reduction
JP4445697B2 (ja) *	2002-08-30	2010-04-07	独立行政法人理化学研究所	生体組織接着剤と親和性を有する生体修復材料
US20050125033A1 (en) *	2003-12-04	2005-06-09	Mcnally-Heintzelman Karen M.	Wound closure apparatus
US20050125015A1 (en) *	2003-12-04	2005-06-09	Mcnally-Heintzelman Karen M.	Tissue-handling apparatus, system and method
SE0303588D0 (sv) *	2003-12-30	2003-12-30	Bioactive Polymers Ab C O Lund	Surface protection of exposed biological tissues
US20050283004A1 (en) *	2004-06-18	2005-12-22	Hopax Chemicals Manufacturing Co., Ltd.	Alkylsulfonated polyaminosaccharides
US8419722B2 (en) *	2004-10-29	2013-04-16	Spinal Restoration, Inc.	Apparatus and method for injection of fibrin sealant in spinal applications
US8206448B2 (en)	2004-10-29	2012-06-26	Spinal Restoration, Inc.	Injection of fibrin sealant using reconstituted components in spinal applications
US7597687B2 (en) *	2004-10-29	2009-10-06	Spinal Restoration, Inc.	Injection of fibrin sealant including an anesthetic in spinal applications
US20110213464A1 (en) *	2004-10-29	2011-09-01	Whitlock Steven I	Injection of fibrin sealant in the absence of corticosteroids in spinal applications
AU2005317689B2 (en)	2004-12-20	2011-05-12	Amo Groningen B.V.	Amphiphilic block copolymers and their use
US7767656B2 (en) *	2005-04-25	2010-08-03	Molly S Shoichet	Blends of temperature sensitive and anionic polymers for drug delivery
US20070031468A1 (en) *	2005-08-04	2007-02-08	Endomedix, Inc.	Modified chitosan for vascular embolization
US20070031467A1 (en) *	2005-08-04	2007-02-08	Abrahams John M	Composition and method for vascular embolization
CA2640185A1 (fr) *	2006-01-24	2007-08-02	Christopher J. Centeno	Methode et systeme d'isolation et de transplantation de cellules souches mesenchymateuses a utiliser en milieu clinique
US20080075657A1 (en) *	2006-04-18	2008-03-27	Abrahams John M	Biopolymer system for tissue sealing
US7854923B2 (en) *	2006-04-18	2010-12-21	Endomedix, Inc.	Biopolymer system for tissue sealing
US20070243130A1 (en) *	2006-04-18	2007-10-18	Weiliam Chen	Biopolymer system for tissue sealing
EP2010238A2 (fr) *	2006-04-20	2009-01-07	Vivolution A/S	Composition améliorée de colle à la fibrine et utilisation de cette dernière
US20080124395A1 (en) *	2006-06-22	2008-05-29	Weiliam Chen	Formulations and devices for treatment or prevention of neural ischemic damage
EP2106263B1 (fr) *	2007-01-04	2016-12-21	Hepacore Ltd.	Dérivés réactifs solubles dans l'eau de carboxy polysaccharides et conjugués à base de carboxy polysaccharides et du fibrinogène
US9095562B2 (en)	2007-07-05	2015-08-04	Regenerative Sciences, Inc.	Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
CN101945994A (zh) *	2007-12-19	2011-01-12	再生科学有限责任公司	促进干细胞移植和植入的组合物和方法
US20110052533A1 (en) *	2008-03-14	2011-03-03	Regenerative Sciences, Llc	Compositions and Methods for Cartilage Repair
CA2720206C (fr) *	2008-04-04	2016-10-04	Curaseal, Inc.	Dispositif implantable d'obturation de fistule
WO2009151414A1 (fr) *	2008-06-10	2009-12-17	Endomedix, Inc.	Feuillet adhérent biocompatible pour suture des tissus
CA2735748C (fr)	2008-09-04	2017-08-29	Curaseal Inc.	Dispositif gonflable pour le traitement d'une fistule enterique
EP2362789A2 (fr) *	2008-11-03	2011-09-07	Metamorefix Ltd.	Adhésif tissulaire
US20110245804A1 (en)	2008-12-05	2011-10-06	Regenerative Sciences, Llc	Methods and Compositions to Facilitate Repair of Avascular Tissue
US20100168022A1 (en) *	2008-12-11	2010-07-01	Centeno Christopher J	Use of In-Vitro Culture to Design or Test Personalized Treatment Regimens
US8469936B2 (en) *	2009-07-15	2013-06-25	Kci Licensing, Inc.	Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers
US20110054929A1 (en) *	2009-09-01	2011-03-03	Cell Solutions Colorado Llc	Stem Cell Marketplace
US9113950B2 (en)	2009-11-04	2015-08-25	Regenerative Sciences, Llc	Therapeutic delivery device
EP2512516B1 (fr)	2009-12-18	2016-02-17	The Governing Council Of The University Of Toronto	Composition polymère injectable utilisée comme véhicule pour l'administration de cellules
WO2012140650A2 (fr)	2011-04-12	2012-10-18	Hepacore Ltd.	Conjugués de carboxy polysaccharides avec des facteurs de croissance des fibroblastes et variants de ceux-ci
WO2012174469A2 (fr)	2011-06-16	2012-12-20	Curaseal Inc.	Dispositifs de traitement de fistules et procédés associés
EP2720623A4 (fr)	2011-06-17	2015-04-22	Curaseal Inc	Dispositifs et procédés de traitement de fistules
AU2012275335B2 (en)	2011-06-29	2017-04-20	Biorestorative Therapies, Inc.	Brown fat cell compositions and methods
US20130202675A1 (en)	2012-02-03	2013-08-08	Dynasil Biomedical Corporation	Systems and methods for the fabrication of tissue patches
AR091031A1 (es)	2012-05-14	2014-12-30	Teijin Ltd	Producto en planchas y material hemostatico
US9040093B2 (en)	2013-03-13	2015-05-26	Orthovita, Inc.	Bone graft materials containing calcium phosphate and chitosan
CA2910017C (fr) *	2013-04-22	2022-07-05	Sealantium Medical Ltd	Patchs adhesifs tissulaires a base de fibrinogene
US20160051723A1 (en) *	2014-08-21	2016-02-25	Gregory J. Pomrink	Bioresorbable tissue repair composition
WO2016160541A1 (fr)	2015-03-27	2016-10-06	3M Innovative Properties Company	Composition de fibrine, procédé et objets pour plaies
JP2018510005A (ja)	2015-03-31	2018-04-12	ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル	幹細胞の送達媒体およびその使用
CA2994959A1 (fr)	2015-08-07	2017-02-16	Xcede Technologies, Inc.	Compositions adhesives et procedes associes
US9540548B1 (en)	2015-08-07	2017-01-10	Xcede Technologies, Inc.	Adhesive compositions and related methods
US9833538B2 (en)	2015-08-07	2017-12-05	Xcede Technologies, Inc.	Adhesive compositions and related methods
US11471556B2 (en)	2015-10-19	2022-10-18	Sealantium Medical Ltd.	Fibrinogen-based tissue adhesive patch
EP3522941A4 (fr)	2016-10-05	2020-06-17	3M Innovative Properties Company	Composition de fibrinogène, procédé et articles pour plaies
WO2018067628A1 (fr)	2016-10-05	2018-04-12	3M Innovative Properties Company	Composition de fibrine comprenant un matériau support, procédé et objets pour plaies
EP4403194A3 (fr)	2018-11-19	2024-10-16	Endomedix, Inc.	Procédés et compositions pour réaliser une hémostase et une formation stable de caillots sanguins
US10517988B1 (en)	2018-11-19	2019-12-31	Endomedix, Inc.	Methods and compositions for achieving hemostasis and stable blood clot formation
CN112386740A (zh) *	2019-08-15	2021-02-23	孟国路	一种成纤维细胞生长因子自粘性人工硬膜修补片及其制备方法
CN112386741A (zh) *	2019-08-15	2021-02-23	孟国路	一种自粘性止血人工硬膜修补片及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3203775A1 (de)	1982-02-04	1983-08-11	Behringwerke Ag, 3550 Marburg	Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung
US4851521A (en)	1985-07-08	1989-07-25	Fidia, S.P.A.	Esters of hyaluronic acid
US5202431A (en)	1985-07-08	1993-04-13	Fidia, S.P.A.	Partial esters of hyaluronic acid
IT1198449B (it)	1986-10-13	1988-12-21	F I D I Farmaceutici Italiani	Esteri di alcoli polivalenti di acido ialuronico
AT397203B (de)	1988-05-31	1994-02-25	Immuno Ag	Gewebeklebstoff
SE9101853D0 (sv) *	1991-06-17	1991-06-17	Jonas Wadstroem	Improved tissue ashesive
AU4566893A (en) *	1992-07-18	1994-02-14	Opperbas Holding B.V.	A two component fibrin-glue composition for improving in vitro fertilization
US5395923A (en)	1993-02-23	1995-03-07	Haemacure-Biotech, Inc.	Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
US5290918A (en)	1993-02-23	1994-03-01	Haemacure Biotech Inc.	Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
EP0796115A1 (fr) *	1994-12-07	1997-09-24	The American National Red Cross	Colles tissulaires adjuventees et non adjuventees, procedes de production et d'utilisation
GB9424732D0 (en)	1994-12-08	1995-02-08	Common Services Agency	Heat treated blood plasma proteins
US5510102A (en) *	1995-01-23	1996-04-23	The Regents Of The University Of California	Plasma and polymer containing surgical hemostatic adhesives
WO1996040174A1 (fr) *	1995-06-07	1996-12-19	The American National Red Cross	Produits d'obturation tissulaires completes et non completes, leurs procedes de production et d'utilisation
DE19521324C1 (de) *	1995-06-12	1996-10-31	Immuno Ag	Gewebeklebstoff und Verwendung desselben als Hämostyptikum
AU4648697A (en) *	1996-09-23	1998-04-14	Chandrashekar Pathak	Methods and devices for preparing protein concentrates
ATE439150T1 (de) *	1997-11-17	2009-08-15	Haemacure Corp	Ein hyaluronsäurederivat enthaltende fibrinsiegel-oder fibrinklebmasse

1998
- 1998-11-17 AT AT98963761T patent/ATE439150T1/de not_active IP Right Cessation
- 1998-11-17 WO PCT/US1998/024605 patent/WO1999025782A2/fr not_active Ceased
- 1998-11-17 EP EP98963761A patent/EP1032367B1/fr not_active Expired - Lifetime
- 1998-11-17 CA CA002308462A patent/CA2308462C/fr not_active Expired - Fee Related
- 1998-11-17 US US09/554,745 patent/US6503527B1/en not_active Expired - Lifetime
2000
- 2000-05-05 NO NO20002357A patent/NO326601B1/no not_active IP Right Cessation
2003
- 2003-01-06 US US10/336,936 patent/US6699484B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6699484B2 (en)	2004-03-02
NO20002357L (no)	2000-06-14
NO20002357D0 (no)	2000-05-05
US20030103961A1 (en)	2003-06-05
ATE439150T1 (de)	2009-08-15
US6503527B1 (en)	2003-01-07
WO1999025782A2 (fr)	1999-05-27
EP1032367A4 (fr)	2005-02-02
EP1032367A2 (fr)	2000-09-06
CA2308462A1 (fr)	1999-05-27
CA2308462C (fr)	2009-02-24
EP1032367B1 (fr)	2009-08-12
WO1999025782A3 (fr)	1999-07-15

Legal Events

Date	Code	Title	Description
2011-06-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
EP1032367B1 (fr)	2009-08-12	Agents de scellement ou adhesifs comprenant un materiau derive d'acide hyaluronique
Sierra	1993	Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications
Brennan	1991	Fibrin glue
Martinowitz et al.	1996	Fibrin sealant
US4818291A (en)	1989-04-04	Silk-fibroin and human-fibrinogen adhesive composition
Dickneite et al.	2003	A comparison of fibrin sealants in relation to their in vitro and in vivo properties
US5510102A (en)	1996-04-23	Plasma and polymer containing surgical hemostatic adhesives
US8821861B2 (en)	2014-09-02	Fibrin sealant
CA2696255C (fr)	2016-11-29	Reticulation photoactivee d'une proteine ou d'un peptide
US20100256671A1 (en)	2010-10-07	Tissue sealant for use in noncompressible hemorrhage
US20130149292A1 (en)	2013-06-13	Thrombin-free biological adhesive and use thereof as a medicament
EA006700B1 (ru)	2006-02-24	Носитель с твердым фибриногеном и твердым тромбином
CA2330972C (fr)	2008-08-19	Compositions d'adhesif tissulaire entierement recombinantes
US6780411B2 (en)	2004-08-24	Tissue sealant compositions
RU2556960C2 (ru)	2015-07-20	Способ обеспечения улучшенного уплотнения с помощью фибрина
JPH02129224A (ja)	1990-05-17	フィブリンの製造法
Kjaergard et al.	2000	Comparative kinetics of polymerisation of three fibrin sealants and influence on timing of tissue adhesion
US20150359857A1 (en)	2015-12-17	Aerosolized fibrin hemostat
CH681693A5 (fr)	1993-05-14
US6558687B2 (en)	2003-05-06	Fibrin polymer structure
Redl et al.	1985	Principles of fibrin sealant and its mode of application
Karmaker	2021	Development and characterization of autologous fibrin glue augmented with biocompatible polymers
Drake et al.	2001	Fibrin sealants in microvascular surgery: Current status
RU2275201C2 (ru)	2006-04-27	Гемостатический клей
Joel et al.	2006	BIOADHESIVE TECHNOLOGY■